Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Mistelbach – page 71

889 clinical trials in Mistelbach, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Mistelbach at a glance
889
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

889 trials in Mistelbach

Open in trial search

Macular oedema

Not recruiting

Study on the Effects of RO7200220 for Adults and Children with Uveitic Macular Edema

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Vamikibart
  • Sponsor:F. Hoffmann-La Roche AG

Study on Vericiguat for Adults with Chronic Heart Failure with Reduced Ejection Fraction

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Vericiguat
  • Sponsor:Merck Sharp & Dohme LLC

Malignant melanoma

Not recruiting

Study on Nivolumab for Preventing Melanoma Recurrence in Patients with Completely Removed Stage IIB/C Melanoma

Registered drug
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Hidradenitis

Not recruiting

Study on the Effectiveness and Safety of Povorcitinib for Patients with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Povorcitinib
  • Sponsor:Incyte Corp.

Study Comparing Docetaxel, Darolutamide, and ADT for Patients with Metastatic Hormone-Sensitive Prostate Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Buserelin Acetate
  • Sponsor:Friedrich-Schiller-Universitaet Jena

Hidradenitis

Not recruiting

Study to Evaluate the Effectiveness of Spesolimab for Patients with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Spesolimab
  • Sponsor:Boehringer Ingelheim Espana S.A.

Portal hypertension

Not recruiting

Study on BI 685509 and Empagliflozin for Patients with Portal Hypertension in Compensated Cirrhosis

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:BI 685509
  • Sponsor:Boehringer Ingelheim Espana S.A.

Cardiac amyloidosis

Not recruiting

Study on Long-Term Safety of Eplontersen for Adults with Transthyretin-Mediated Amyloid Cardiomyopathy

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ascorbic Acid
  • Sponsor:Ionis Pharmaceuticals Inc.

Long-Term Follow-Up Study of Imlifidase in Highly Sensitized Kidney Transplant Patients

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Imlifidase
  • Sponsor:Hansa Biopharma AB

Diabetic neuropathy+1

Not recruiting

Study on the Effectiveness and Safety of AP707, Amitriptyline, and Capsaicin for Patients with Chronic Pain from Diabetic Neuropathy

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Adezunap
  • Sponsor:Apurano Pharmaceuticals GmbH

Study on Milvexian for Preventing Stroke in Patients with Acute Ischemic Stroke or High-Risk Transient Ischemic Attack

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Janssen - Cilag International

Cardiac failure+1

Not recruiting

Study of AZD3427 for Patients with Heart Failure and Pulmonary Hypertension from Left Heart Disease

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:AZD3427
  • Sponsor:Astrazeneca AB

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Mistelbach

What the registry says about research in the country

01 Cardiovascular Research

Groundbreaking studies focusing on stroke prevention and management of atrial fibrillation. Research evaluates innovative treatments comparing asundexian to established medications for reducing stroke risk in patients with irregular heartbeat.

  • Stroke Prevention
  • Atrial Fibrillation Management
  • Systemic Embolism Prevention

Trials aim to assess both effectiveness and safety profiles of new therapeutic approaches.

02 Oncology Studies

Advanced research in breast cancer treatment, specifically focusing on hormone receptor-positive/HER2-negative early breast cancer. Studies evaluate the effectiveness of combining palbociclib with standard endocrine therapy.

  • Early Breast Cancer Treatment
  • Endocrine Therapy Enhancement
  • Disease-Free Survival Assessment

Research aims to improve treatment outcomes through innovative combination therapies.

03 Neurology Research

Innovative studies examining treatments for acute ischemic stroke and high-risk transient ischemic attacks. Research evaluates the efficacy of milvexian in reducing stroke risk compared to placebo.

  • Acute Stroke Treatment
  • Ischemic Attack Prevention
  • Neurological Recovery

Focus on developing more effective interventions for stroke prevention and management.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.